X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Day One receives an exclusive license to develop and commercialize small molecule drug candidates targeting Vaccinia-related kinase 1 (VRK1), for pediatric and adult cancers with high unmet need.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Day One Biopharmaceuticals
Deal Size: $316.0 million Upfront Cash: $3.0 million
Deal Type: Licensing Agreement August 16, 2023
Details:
Sprint Bioscience lead compound SB02024 blocks the autophagy of tumor cells by inhibiting the protein Vps34. When autophagy is blocked, the tumor cells become visible to the immune system again.
Lead Product(s): SB02024
Therapeutic Area: Oncology Product Name: SB02024
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Deciphera Pharmaceuticals
Deal Size: $277.0 million Upfront Cash: $4.0 million
Deal Type: Licensing Agreement August 03, 2021
Details:
The research results show that SB02024 activates the immune system in tumors in malignant melanoma and colorectal cancer.
Lead Product(s): SB02024
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 30, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
